Tango Therapeutics, Inc.

Tango Therapeutics, Inc., traded under the ticker BCTG on Nasdaq, is a clinical-stage biopharmaceutical company focused on precision oncology that came to market through a SPAC transaction with BCTG Acquisition Corp, which completed its IPO in 2020. The SPAC targeted the life sciences and healthcare sector, and the combination with Tango Therapeutics represented a de-SPAC merger in the oncology space. The company filed a 10-Q quarterly report on May 14, 2021, with accession number 0001213900-21-026397, reflecting its reporting obligations during the post-combination period. Tango's pipeline centers on synthetic lethality approaches to cancer treatment. Sign up for full data, filings history, and deal analytics on SpacDesk.